Intellia Therapeutics, Inc.
NTLA
$13.42
-$0.06-0.45%
NASDAQ
| 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | |
|---|---|---|---|---|---|
| Net Income | -95.79M | -101.32M | -101.26M | -114.33M | -128.90M |
| Total Depreciation and Amortization | 6.02M | 4.94M | 2.47M | 2.50M | 2.57M |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 19.99M | 15.08M | 19.03M | 21.69M | 39.10M |
| Change in Net Operating Assets | 494.00K | 4.41M | -19.87M | -58.78M | 2.04M |
| Cash from Operations | -69.29M | -76.90M | -99.62M | -148.93M | -85.20M |
| Capital Expenditure | -126.00K | -29.00K | -239.00K | -735.00K | -981.00K |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | 27.66M | -712.00K | 107.15M | 95.06M | 152.55M |
| Cash from Investing | 27.53M | -741.00K | 106.91M | 94.33M | 151.57M |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | 1.98M | 114.86M | 14.65M | -- | 2.32M |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | 1.98M | 114.86M | 14.65M | -- | 2.32M |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -39.77M | 37.22M | 21.94M | -54.60M | 68.69M |